TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00856388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Description: Undergo total-body irradiation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Description: Undergo allogeneic stem cell transplantation
Study: NCT04645524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD182
Description: Oral capsule administered before bed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD504
Description: Oral capsule administered before bed
Study: NCT00856388

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin
Description: Given IV
Study: NCT01439880

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Administered by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Evolocumab
Description: Administered by subcutaneous injection

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Standard of care therapy as per local practices. This could include prescribed therapies and/or dietary/exercise regimes
Study: NCT04645524

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsule administered before bed

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Polysomnography
Description: for all arms

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Polysomnography
Description: for all arms
Study: NCT04344106

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prone positioning
Description: The prone positioning consists of placing the patient on his or her stomach with the head on the side, during sessions lasting several hours a day.
Study: NCT03627780

Intervention type: DIAGNOSTIC_TEST
Intervention: DNA extraction
Description: DNA will be extracted from white cells

Intervention type: DIAGNOSTIC_TEST
Intervention: DNA extraction
Description: DNA will be extracted from white cells
Study: NCT00722124

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-Adenosyl-L-Methionine
Description: 800 mg dose per day for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-Adenosyl-L-Methionine
Description: 1600 mg per day for 8 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 4 pills (2 in the AM and 2 in the PM) of placebos for 8 weeks
Study: NCT03368508

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simulating video
Description: A 360-degree simulating video showing physiotherapy assessment in lumbar area

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional video
Description: A conventional video showing physiotherapy assessment in lumbar area
Study: NCT00569153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-700
Description: Phase 1 portion of study:~TAK-700 dose escalation. Tablets administered orally, twice daily until disease progression or occurrence of an unacceptable adverse event.~Phase 2 portion of study:~Patients will receive one of 4 treatments:~* TAK-700 at 300 mg twice/day~* TAK-700 at 400 mg and 5 mg prednisone twice/day~* TAK-700 at 600 mg and 5 mg prednisone twice/day~* TAK-700 at 600 mg once/day in the morning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-700
Description: Phase 1 portion of study:~TAK-700 dose escalation. Tablets administered orally, twice daily until disease progression or occurrence of an unacceptable adverse event.~Phase 2 portion of study:~Patients will receive one of 4 treatments:~* TAK-700 at 300 mg twice/day~* TAK-700 at 400 mg and 5 mg prednisone twice/day~* TAK-700 at 600 mg and 5 mg prednisone twice/day~* TAK-700 at 600 mg once/day in the morning
Study: NCT04645524

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Polysomnography
Description: for all arms
Study: NCT04322370

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Surgical Procedure
Description: Zone 2 Flexor Tendon surgical repair will be performed by the principal investigator per standard of care. The same technique of tendon repair will be performed for all patients.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VersaWrap Treatment
Description: is intended to manage and protect tendon injuries where there is no significant loss of tendon tissue
Study: NCT03493659

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standing during Concept Test
Description: The participants will stand with a standing desk at an ergonomically correct height during the administration of the Concept Test.
Study: NCT02708589

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: probiotic
Study: NCT01687790

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: molecular breast imaging (Discovery)
Study: NCT03493659

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standing during regular tutorial session
Description: The participants will stand with a standing desk at an ergonomically correct height during their regular tutorial sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standing during Concept Test and regular tutorial session
Description: The participants will stand with a standing desk at an ergonomically correct height during the administration of the Concept Test and during their regular tutorial sessions.
Study: NCT03158792

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin 20Mg/0.2mL Prefilled Syringe
Description: Enoxaparin 20mg subcutaneously once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin 60Mg/0.6Ml Inj Syringe 0.6Ml
Description: Enoxaparin 30mg subcutaneously once daily. Half of the graduated 60Mg/0.6Ml Inj Syringe is administered
Study: NCT01368718

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Active CPAP is compared with sham CPAP as a control intervention.
Description: Patients are randomized into active or control arm. After the first treatment, a washout period is installed,after which therapy is switched according to the cross-over protocol. A CPAP device consists of a unit that generates airflow, which is directed to the airway via a mask. With active CPAP, the generated airflow creates a positive pressure and prevents upper airway collapse. With sham CPAP, the generated airflow creates a very low pressure.
Study: NCT03907618

Intervention type: DIAGNOSTIC_TEST
Intervention: ovarian reserve
Description: To assess ovarian reserve in patients with Type 1 Diabetes Mellitus aged 18-40 years; ultrasonographic and laboratory parameters will be looked at.

Intervention type: DIAGNOSTIC_TEST
Intervention: ovarian reserve
Description: To assess ovarian reserve in patients with Type 1 Diabetes Mellitus aged 18-40 years; ultrasonographic and laboratory parameters will be looked at.
Study: NCT04335487

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PSP PTSD Course
Description: A tailored ICBT intervention designed to treat symptoms of PTSD will be delivered to public safety personnel. Clients will be offered once a week support, but support can be increased to twice a week support if PSP request extra support. The intervention is designed to be completed in 8 weeks, but clients will be able to extend their treatment by an additional 8 weeks (i.e., up to 16 weeks in total).
Study: NCT00918060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camella sinensis gel
Description: clinical effect of locally-delivered gel between Camella sinensis and placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Camella sinensis gel
Description: clinical effect of locally-delivered gel between Camella sinensis and placebo
Study: NCT02412488

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Out of cathlab insertion
Description: Insertion of the Reveal LINQ device in the out-of-cathlab setting (out of the operating room, cardiac catheterization or electrophysiology laboratory).
Study: NCT01634425

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alere Triage Meter Pro
Description: Troponin and BNP measured on point of care meter.
Study: NCT02489916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM4307
Description: CM4307 300mg bid, each 4 week cycle
Study: NCT01813045

Intervention type: PROCEDURE
Intervention: Cardiac MRI scan
Description: Cardiac MRI scan with assessment of late gadolinium enhancement and T1 mapping.

Intervention type: PROCEDURE
Intervention: Cardiac MRI scan
Description: Cardiac MRI scan with assessment of late gadolinium enhancement and T1 mapping.

Intervention type: PROCEDURE
Intervention: Cardiac MRI scan
Description: Cardiac MRI scan with assessment of late gadolinium enhancement and T1 mapping.

Intervention type: RADIATION
Intervention: CT-PET scan
Description: Computed Tomography / Positron Emission Tomography scan with 18F-fluciclatide tracer.

Intervention type: RADIATION
Intervention: CT-PET scan
Description: Computed Tomography / Positron Emission Tomography scan with 18F-fluciclatide tracer.

Intervention type: RADIATION
Intervention: CT-PET scan
Description: Computed Tomography / Positron Emission Tomography scan with 18F-fluciclatide tracer.

Intervention type: RADIATION
Intervention: CT-coronary angiogram
Description: CT-coronary angiogram following CT-PET scan. Standard protocol.

Intervention type: RADIATION
Intervention: CT-coronary angiogram
Description: CT-coronary angiogram following CT-PET scan. Standard protocol.

Intervention type: RADIATION
Intervention: CT-coronary angiogram
Description: CT-coronary angiogram following CT-PET scan. Standard protocol.
Study: NCT02409108

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exatherm-TBH system
Description: One treatment of Total Body Hyperthermia
Study: NCT04381988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: 400mg daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 400mg daily

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Standard radiation therapy will be prescribed and administered as per the patient's radiation oncologist.

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Radiation therapy
Description: Standard radiation therapy will be prescribed and administered as per the patient's radiation oncologist.
Study: NCT01323920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib 1.3 mg/m\^2 IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus 0.05 mg/kg PO bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate 15 mg/m\^2 IV
Study: NCT04111978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5mg
Description: Aromatase inhibitor

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet of Femara
Study: NCT00081510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lonafarnib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anastrozole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anastrozole
Study: NCT01463137

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Attention bias modification
Description: All arms will consist of 10 minutes of training in front of a computer screen (192 trials) once a day for 14 days.
Study: NCT02708589

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01463137

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Attention bias modification
Description: All arms will consist of 10 minutes of training in front of a computer screen (192 trials) once a day for 14 days.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention bias modification
Description: All arms will consist of 10 minutes of training in front of a computer screen (192 trials) once a day for 14 days.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention bias modification
Description: All arms will consist of 10 minutes of training in front of a computer screen (192 trials) once a day for 14 days.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention bias modification
Description: All arms will consist of 10 minutes of training in front of a computer screen (192 trials) once a day for 14 days.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention bias modification
Description: All arms will consist of 10 minutes of training in front of a computer screen (192 trials) once a day for 14 days.
Study: NCT03940976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: Afatinib is orally administered at 40mg Qd of each 28 day cycle.
Study: NCT02195011

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SIR-Spheres
Description: Radioembolization will be administered once by injection through a trans-femoral catheter into the hepatic artery.
Study: NCT04335487

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PSP Wellbeing Course
Description: A tailored ICBT intervention designed to treat symptoms of depression, anxiety, or PTSD will be delivered to public safety personnel. Clients will be offered once a week support, but support can be increased to twice a week support if PSP request extra support. The intervention is designed to be completed in 8 weeks, but clients will be able to extend their treatment by an additional 8 weeks (i.e., up to 16 weeks in total).
Study: NCT00699192

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine 5 mg
Description: 1 capsule amlodipine 5 mg orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine 5 mg
Description: 1 capsule amlodipine 5 mg orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg
Description: 1 capsule amlodipine 5 mg orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan 80 mg
Description: 1 capsule valsartan 80 mg orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan 40 mg
Description: 1 capsule valsartan 40 mg orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 1 capsule placebo to match valsartan orally once daily
Study: NCT00837187

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous dexmedetomidine
Description: 100 ug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine
Description: 100 ug
Study: NCT00341328

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intradermal injection of Mycobacterium w
Description: Mw Vaccine is given as intradermal administration. Total 6 doses are given 0.2 ml at baseline and then 0.1 ml after interval of 2 weeks upto 8 weeks

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Intradermal injection of Mycobacterium w
Description: Mw Vaccine is given as intradermal administration. Total 6 doses are given 0.2 ml at baseline and then 0.1 ml after interval of 2 weeks upto 8 weeks
Study: NCT04866927

Intervention type: DIETARY_SUPPLEMENT
Intervention: Use of stable isotopic dilution to assess protein digestibility from Faba bean and to evaluate amino acid bioavailability
Description: Each participant will receive a test meal containing 13C labelled spirulina, 2H labelled Fava bean and 13C phenylalanine. The test meal will be divided on 11 subdoses: 3 sub-doses will be administrated at T0 and 1 subdose will be administrated at 1, 2, 3, 4, 5, 6 and 7h. The remaining sub-dose will be kept for measurement of IAA in the test meal. After eating the test meal, blood, urine and breath samples will be collected from each participant at the baseline (T0) and after 5-6, 7h and 8h.
Study: NCT04587115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: Risperidone 1mg to be used in combination with other drugs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Description: Ziprasidone 80mg to be used in combination with other study drugs

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxycodone
Description: Oxycodone alone in a capsule will be considered the control. Oxycodone 15 mg will also be used in combination with other study drugs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: Oxycodone alone in a capsule will be considered the control. Oxycodone 15 mg will also be used in combination with other study drugs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: Oxycodone alone in a capsule will be considered the control. Oxycodone 15 mg will also be used in combination with other study drugs
Study: NCT03514914

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The CHARM2 Intervention
Description: CHARM2 intervention will involve gender, culture \& contextually-tailored family planning and gender equity counseling.
Study: NCT00369447

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: External radiotherapy
Description: Radiotherapy for first 2 weeks, 10 daily fractions of 30Gy 2 additional fractions to be added if desirable

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: External radiotherapy
Description: Radiotherapy for first 2 weeks, 10 daily fractions of 30Gy 2 additional fractions to be added if desirable
Study: NCT02878213

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: D700 System
Description: Atrial Fibrillation Ablation Procedure
Study: NCT03149341

Intervention type: OTHER
Intervention: Magnetic Resonance Imaging
Description: All subjects will undergo or have already undergone Magnetic Resonance Imaging. Normal volunteers will be used for comparison with subjects. To minimize risk, normal volunteers will NOT undergo anesthesia, sedation or receive intravenous contrast during procedure.

Intervention type: OTHER
Intervention: Magnetic Resonance Imaging
Description: All subjects will undergo or have already undergone Magnetic Resonance Imaging. Normal volunteers will be used for comparison with subjects. To minimize risk, normal volunteers will NOT undergo anesthesia, sedation or receive intravenous contrast during procedure.
Study: NCT02619227

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Livelihood intervention
Description: Participants will receive a livelihood intervention package consisting of a orientation and training and a loan package of chickens and associated implements to create poultry microenterprises.
Study: NCT00369447

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: nimotuzumab
Description: weekly dose until disease progression
Study: NCT03511079

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music
Description: Music will be delivered through Pandora Plus radio via patient's computer or smartphone. The patient will choose a favorite song to create a playlist which will be used for the duration of the entire study. The subgenre of the initial song will be recorded.
Study: NCT04600297

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ELS Even Stronger (3D Printed Resin Composite)
Description: Missing of one premolar cases will be restored using the 3D Printed resin composite (ELS Even Stronger, Saremco, Switzerland). The steps of the procedure: Preparation, scanning, colour determination, design of the restoration, printing the restoration, adjusting occlusion, finishing and polishing, cementation.
Study: NCT00158522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated interferon alpha2a
Study: NCT00656916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate
Description: 440 micrograms twice daily by oral inhalation.
Study: NCT04297241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isosorbide Dinitrate
Description: All patients will be given a 6 week titration regimen of study medication. Patients will begin at a 5mg dosage and titrate up to 30mg three times per day if each subsequent dose is tolerated.
Study: NCT00369447

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: nimotuzumab
Description: weekly dose until disease progression
Study: NCT03888430

Intervention type: PROCEDURE
Intervention: PtcCO2 measure during intubation
Description: Transcutaneous measure during intubation. Non invasive measure without any risk according to the literature

Intervention type: PROCEDURE
Intervention: PtcCO2 measure during intubation
Description: Transcutaneous measure during intubation. Non invasive measure without any risk according to the literature

Intervention type: PROCEDURE
Intervention: PtcCO2 measure during intubation
Description: Transcutaneous measure during intubation. Non invasive measure without any risk according to the literature
Study: NCT02943447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilofexor
Description: Tablet(s) administered orally once daily, with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilofexor
Description: Tablet(s) administered orally once daily, with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilofexor
Description: Tablet(s) administered orally once daily, with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match cilofexor
Description: Tablet(s) administered orally once daily, with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match cilofexor
Description: Tablet(s) administered orally once daily, with food

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match cilofexor
Description: Tablet(s) administered orally once daily, with food
Study: NCT03239990

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incredible Years, Parent group supported by home visiting
Description: Parents are taught to use positive and consistent strategies in reducing child misbehavior
Study: NCT04613258

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: SCAR Porridge
Description: The treatment group was given SCAR porridge supplementation in the form of a soft porridge (a mixture of 50 g dry powder porridge added to 200 mL of hot water) along with nutritional counseling. The control group only received nutritional counseling and no SCAR porridge supplementation. A 50 g portion of SCAR porridge was provided once a day for 14 days. The SCAR porridge was monitored and administered by a researcher once a week to inquire about adherence to the supplementation consumption and perceived side effects. All research subjects went through a clearance period of one week and were requested not to consume any supplements.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Counseling
Description: 21 subjects in the control group (C) who only received dietary counseling